TFAP2A enhances radioresistance of non-small cell lung cancer by transcriptionally activating BRCA1
Radioresistance remains a major obstacle in the treatment of non-small cell lung cancer (NSCLC). Transcription factor AP-2α (TFAP2A) has been implicated in tumor progression, but its role in NSCLC radioresistance and translational therapeutic relevance remain unclear. Bioinformatics analyses of TCGA and GEO datasets we...